by
Lisa Chamoff, Contributing Reporter | October 18, 2021
From the October 2021 issue of HealthCare Business News magazine
The company is also expanding use of the Xoft System for the treatment of various types of brain tumors, such as recurrent glioblastoma multiforme. An ongoing study in Russia has been comparing patients who received a craniotomy and traditional treatment to patients who have undergone surgery and intraoperative radiation therapy with the Xoft technology.
“Patients in the external beam control group lived up to two years, whereas survival in the IORT group ranged up to four and a half years after treatment,” said Stacey Stevens, president of iCAD. “This research is extremely promising and demonstrates the Xoft System’s versatility as a viable treatment option for various types of tumors.”
Ad Statistics
Times Displayed: 109208
Times Visited: 6638 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
The company hopes to replicate the results in a study of 80 to 100 patients. There are also plans to expand use of the Xoft System to prostate cancer treatment in the future.
ZAP Surgical
Over the past year, ZAP Surgical has received CE marking and Shonin approval from the Japanese Pharmaceuticals and Medical Devices Agency for its ZAP-X Gyroscopic Radiosurgery Platform, the first and only vault-free and cobalt-free dedicated cranial stereotactic radiosurgery (SRS) system.
The system, FDA cleared in 2017, eliminates the high costs of building shielded radiation treatment rooms and the costs to license, secure and regularly replace live radioactive isotopes, said Mark Arnold, senior vice president of marketing for ZAP Surgical.
While estimates indicate there are more than two million potential SRS patient candidates each year, only 150,000 are treated due to the significant costs and complexities of historical delivery technologies, according to Arnold.
“Our goal is to bring world-class SRS to the two million-plus patients a year who currently lack access,” Arnold said.
The device was invented by Dr. John R. Adler, Stanford neurosurgeon, inventor of the CyberKnife and former chief medical officer of Varian Medical Systems. The device includes a dual-gantry design and uses gyroscopic mobility to direct radiation beams from hundreds of unique angles to concentrate radiation to the tumor target while helping to spare surrounding healthy brain tissue.
“There is greater solid-angle beam coverage as ZAP-X is not limited by the clockwise and counterclockwise rotations commonplace with multipurpose radiation delivery platforms,” Arnold said.
To date, there are seven systems in clinical use and more than 25 sites around the world at varied stages of site planning and installation, spanning large academic institutions, small community hospitals, free-standing clinics and even small outpatient surgical centers.
“We’re seeing uptake that has well exceeded expectations,” Arnold said. “We scaled our 2020 targets back due to COVID, but ended 2020 exceeding pre-pandemic goals.”
Back to HCB News
